PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Acumen Pharmaceuticals, Inc. (ABOS)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS00509G2093
CUSIP00509G209
SectorHealthcare
IndustryBiotechnology

Highlights

Market Cap$236.85M
EPS-$1.11
Revenue (TTM)$329.00K
Gross Profit (TTM)-$32.36M
EBITDA (TTM)-$56.85M
Year Range$1.81 - $11.31
Target Price$14.00
Short %1.62%
Short Ratio2.26

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds to compare with ABOS

Acumen Pharmaceuticals, Inc.

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Acumen Pharmaceuticals, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%20.00%OctoberNovemberDecember2024FebruaryMarch
-79.20%
18.45%
ABOS (Acumen Pharmaceuticals, Inc.)
Benchmark (^GSPC)

S&P 500

Returns By Period

Acumen Pharmaceuticals, Inc. had a return of 8.85% year-to-date (YTD) and 8.01% in the last 12 months.


PeriodReturnBenchmark
Year-To-Date8.85%7.28%
1 month27.44%2.23%
6 months-24.41%14.98%
1 year8.01%30.65%
5 years (annualized)N/A12.59%
10 years (annualized)N/A10.61%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
2024-17.19%35.53%
2023-18.65%-31.06%-54.94%28.34%60.00%

Risk-Adjusted Performance

Risk-Adjusted Performance Indicators

This table presents risk-adjusted performance metrics for Acumen Pharmaceuticals, Inc. (ABOS) and compares them with a selected benchmark (^GSPC). These performance indicators assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratioSortino ratioOmega ratioCalmar ratioUlcer Index
ABOS
Acumen Pharmaceuticals, Inc.
0.02
^GSPC
S&P 500
2.64

Sharpe Ratio

The current Acumen Pharmaceuticals, Inc. Sharpe ratio is 0.02. A Sharpe ratio between 0 and 1.0 is considered sub-optimal.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00OctoberNovemberDecember2024FebruaryMarch
0.02
2.64
ABOS (Acumen Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Acumen Pharmaceuticals, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%OctoberNovemberDecember2024FebruaryMarch
-79.39%
-1.12%
ABOS (Acumen Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Acumen Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Acumen Pharmaceuticals, Inc. was 90.83%, occurring on Nov 9, 2023. The portfolio has not yet recovered.

The current Acumen Pharmaceuticals, Inc. drawdown is 79.39%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-90.83%Jul 6, 2021593Nov 9, 2023

Volatility

Volatility Chart

The current Acumen Pharmaceuticals, Inc. volatility is 19.13%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%OctoberNovemberDecember2024FebruaryMarch
19.13%
3.36%
ABOS (Acumen Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Financials

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM2023202220212020
Revenue

Total Revenue

0.000.000.001.44M1.44M

Cost Of Revenue

145.00K0.00169.00K4.00K8.00K

Gross Profit

-145.00K0.00-169.00K-4.00K1.43M
Operating Expenses

Selling, General & Admin Expenses

13.63M17.13M12.88M7.28M1.35M

R&D Expenses

29.03M39.77M32.36M12.31M8.00M

Total Operating Expenses

42.65M56.90M45.24M19.58M9.35M
Income

Income Before Tax

-35.87M-48.74M-42.86M-100.61M-7.33M

Operating Income

-42.65M-56.90M-45.24M61.57M-7.91M

EBIT

-42.69M0.00-45.24M61.57M-7.91M

Earnings From Continuing Operations

-35.87M-48.74M-42.86M-100.61M-7.33M

Net Income

-34.05M-48.74M-40.48M-181.68M-7.32M

Income Tax Expense

-3.75M0.00-2.38M81.07M-1.00K

Interest Expense

3.71M0.002.38M81.02M0.00

Other Non-Operating Income (Expenses)

4.89M-72.00K2.38M-162.18M587.00K

Extraordinary Items

0.000.000.000.000.00

Discontinued Operations

0.000.000.000.000.00

Effect Of Accounting Charges

0.000.000.000.000.00

Non Recurring

0.000.000.000.000.00

Minority Interest

0.000.000.000.000.00

Other Items

0.000.000.000.000.00
Values in USD except per share items